The abstract is read at the publisher; the summary is JClub's.
A covalent PFKL liver-type activator that site-specifically modifies K677 stabilizes the R-state tetramer and suppresses tumor growth in vitro and in vivo.
- Why it matters: Targeted glycolysis therapies are hard to develop because tumors vary metabolically and can resist single-pathway interventions.
- What they did: The electrophile-drug conjugate selectively modifies PFKL K677 to stabilize the R-state tetramer and simultaneously releases a CPT2-targeting inhibitor to disrupt metabolism.
- The result: By coupling glycolytic activation with CPT2 inhibition via covalent intracellular delivery, the approach suppresses tumor growth and suggests a strategy to overcome metabolic heterogeneity and resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.